Sagimet Biosciences Inc. (NASDAQ: SGMT)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of palmitate. Its lead drug candidate denifanstat is an oral once-daily pill being evaluated for metabolic dysfunction-associated steatohepatitis (MASH), acne and select solid tumors. A second FASN inhibitor TVB-3567 is also in development for acne. The company focuses on advancing these candidates through clinical trials to address diseases with high unmet need.

Sagimet Biosciences Inc. generates revenue primarily through licensing agreements and milestone payments from collaborators. In July 2023 the company recognized two million dollars of revenue related to a development milestone triggered by the initial dosing of a Phase 3 trial for recurrent glioblastoma under its agreement with Ascletis BioScience Co. Ltd. Under the same agreement Sagimet is eligible to receive up to one hundred twenty-two million dollars in aggregate development and commercial milestones and tiered royalties ranging from high single digits to mid-teens on net sales of licensed products in Greater China. The company currently has no product sales revenue as its drug candidates remain investigational.

Sagimet Biosciences Inc. positions itself within the competitive biopharmaceutical landscape by emphasizing the selectivity and favorable pharmacokinetic profile of its FASN inhibitors. Key competitors in the MASH space include Madrigal Pharmaceuticals with its approved therapy resmetirom and Novo Nordisk with semaglutide both of which target similar patient populations. In the acne market the company faces established topical and systemic therapies as well as other investigational agents. Its competitive advantages stem from the oral once-daily dosing the high selectivity for FASN that limits brain penetration and the demonstrated ability to impact multiple disease pathways such as steatosis inflammation and fibrosis simultaneously.

Sagimet Biosciences Inc. serves patients suffering from metabolic liver disease acne and certain solid tumors. The company’s clinical programs enroll individuals with biopsy-confirmed MASH moderate to severe acne vulgaris and advanced solid tumors such as non-small cell lung cancer with KRAS mutations hepatocellular carcinoma and metastatic castration-resistant prostate cancer. Through its licensing arrangement with Ascletis the company also addresses the Chinese market for acne and potential future indications where the partner holds development and commercialization rights.